Elite in Chronic B-Cell Leukemia (CBCL)

Sebastian Bottcher

Rostock, MV, DE 
Elite in Chronic B-Cell Leukemia (CBCL)
Rostock, MV, DE 
OverviewLocationsClinical Research

Overview

Sebastian Bottcher practices in Rostock, Germany. Mr. Bottcher is rated as an Elite expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 114 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 63 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Male

Locations

Rostock, MV 18057, Germany
Other Locations
Munich, BY, Germany
Freiburg, BW, Germany
Siegen, NW, Germany
Kiel, SH, Germany
St. Marien Hospital, Homburg, SL, Germany
Koeln, NW, Germany
Schleswig, SH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drugs: Ibrutinib, Bortezomib
Study Phase: Phase 1/Phase 2

114 Total Publications

Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology.
Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology.
Journal: Cancers
Published: July 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bottcher's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile